{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:04:08Z","timestamp":1790309048991,"version":"4.1.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Cervical cancer ranks as the four leading cause of cancer death in women worldwide. It is the third most common cancer in India. Most patients present in advanced stages. Concurrent chemoradiation is the standard of treatment for locally advanced cervical cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>The aim of the study was to compare the treatment response and hematological, gastrointestinal, and skin toxicity of cisplatin versus gemcitabine as concurrent chemoradiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      This study was conducted from February 2017 to August 2018. Sixty patients of squamous cell carcinoma cervix with Stage IIB to IIIB were randomly allocated to either weekly gemcitabine (observation arm) 150 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      or cisplatin (control arm) in the dose of 35 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      along with concurrent radiotherapy. Treatment response and toxicities of both drugs were evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Statistical Method:<\/jats:title>\n                    <jats:p>Statistical analysis was conducted using the Statistical Package for the Social Sciences version 20. Descriptive statistics such as frequency, percentages, mean, standard deviation, and range were used to describe the treatment characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Gemcitabine arm has more Grade 2 (23.3% vs. 10%) and Grade 3 (3.3% vs. none) hematological toxicity as compared to cisplatin arm. For gastrointestinal toxicity, Grade 2 toxicity was observed more in cisplatin arm (23.3%) as compared to 13.3% in gemcitabine arm. Skin toxicity was found to be insignificant. There was complete response of 86.7% in cisplatin arm, while 73.3% in gemcitabine arm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Cisplatin has a better treatment response as compared to gemcitabine as concomitant chemotherapy agent with external beam radiation therapy. Hematological toxicity was more in gemcitabine arm and gastrointestinal toxicity was more in cisplatin arm. The skin toxicities were comparable in both the arms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1184_20","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T07:07:26Z","timestamp":1627628846000},"page":"1518-1524","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Cisplatin versus gemcitabine as concurrent chemoradiotherapy in squamous cell carcinoma cervix"],"prefix":"10.4103","volume":"18","author":[{"given":"Ramandeep","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja Paramjeet","family":"Singh Banipal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajya Devi","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20241021","first-page":"27","article-title":"Global cancer statistics 2018: GLOBOCON. Estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"00","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R3-10-20241021","first-page":"31","article-title":"Biologic and clinical developments of cisplatin combined with radiation: Concepts, utility, projections for new trials, and the emergence of carboplatin","volume":"16","author":"Coughlin","year":"1989","journal-title":"Semin Oncol"},{"key":"R4-10-20241021","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s002800100370","article-title":"Gemcitabine activity in cervical cancer cell line","volume":"48","author":"Hernandez","year":"2001","journal-title":"Cancer Chemother Parmacol"},{"key":"R5-10-20241021","first-page":"475","article-title":"Current state of the art of concomitant chemoradiation in carcinoma cervix","volume":"24","author":"Vreololjak","year":"2003","journal-title":"Eur J Gynaecol Oncol"},{"key":"R6-10-20241021","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"340","author":"Rose","year":"1999","journal-title":"N Engl J Med"},{"key":"R7-10-20241021","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJM199904153401503","article-title":"Cisplatin, radiation, adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky Stage 1B cervical carcinoma","volume":"340","author":"Keys","year":"1999","journal-title":"N Eng J Med"},{"key":"R8-10-20241021","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM199904153401501","article-title":"Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer","volume":"340","author":"Morris","year":"1999","journal-title":"N Engl J Med"},{"key":"R9-10-20241021","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2000.18.8.1606","article-title":"Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix","volume":"18","author":"Peters","year":"2000","journal-title":"J Clin Oncol"},{"key":"R10-10-20241021","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1200\/JCO.1999.17.5.1339","article-title":"Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative paraaortic lymphnodes: A gynaecologic oncology group and South West Oncology group study","volume":"17","author":"Whitney","year":"1999","journal-title":"J Clin Oncol"},{"key":"R11-10-20241021","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1006\/gyno.2001.6197","article-title":"Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma","volume":"81","author":"Pattaranutaporn","year":"2001","journal-title":"Gynecol Oncol"},{"key":"R12-10-20241021","doi-asserted-by":"crossref","first-page":"25734","DOI":"10.18535\/jmscr\/v5i7.235","article-title":"Feasibility of weekly cisplatin versus gemcitabine concomitant with radiation in the management of locally advanced carcinoma cervix","volume":"05","author":"Singh","year":"2017","journal-title":"JMSCR"},{"key":"R13-10-20241021","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3802\/jgo.2009.20.4.221","article-title":"Weekly cisplatin or gemcitabine concomitant with radiation in athe management of locally advanced carcinoma cervix","volume":"20","author":"Verma","year":"2009","journal-title":"J Gynecol Oncol"},{"key":"R14-10-20241021","first-page":"4","article-title":"Comparative efficacy of cisplatin vs. gemcitabine as concurrent chemotherapy for untreated locally advanced cervical cancer: A randomized trail","volume":"2","author":"Srivastava","year":"2007","journal-title":"Internet J Med Update"},{"key":"R15-10-20241021","doi-asserted-by":"crossref","first-page":"16012","DOI":"10.1200\/jco.2007.25.18_suppl.16012","article-title":"Evaluation of gemcitabine versus cisplatinum as an adjunct to radiotherapy in locally advanced carcinoma uterine cervix","volume":"25","author":"Bhatt","year":"2007","journal-title":"J Clin Oncol"},{"key":"R16-10-20241021","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/0971-5851.51399","article-title":"Chemoradiation in locally advanced cervical cancer","volume":"29","author":"Kundu","year":"2008","journal-title":"Indian J Med Paediatr Oncol"},{"key":"R17-10-20241021","first-page":"43","article-title":"Concurrent chomoradiotherapy for locally advanced cervical cancer using gemcitabine: Non randomized comparison of three sequential protocols","volume":"5","author":"Chufal","year":"2007","journal-title":"Cancer Ther"},{"key":"R18-10-20241021","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.7150\/jca.40276","article-title":"Tolerability, Efficacy and Feasibility of Concurrent Gemcitabine and Cisplatin (CGP) Combined with intensity modulated radiotherapy for loco-regionally advanced carcinoma of the cervix","volume":"11","author":"Drokow","year":"2020","journal-title":"J Cancer"},{"key":"R19-10-20241021","doi-asserted-by":"crossref","first-page":"1217838","DOI":"10.1155\/2019\/1217838","article-title":"The impact of addition of consolidation chemotherapy to standard cisplatin based chemoradiotherapy in uterine cervical cancer: Matter of distant relapse","volume":"2019","author":"Fabri","year":"2019","journal-title":"J Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1184_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:27Z","timestamp":1787067627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1184_20"}},"subtitle":["A comparative study of clinical response and toxicities"],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1184_20","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}